Chelsea Therapeutics to Present At the Rodman and Renshaw 11th Annual Healthcare Conference On Wednesday, September 9, 2009

CHARLOTTE, N.C., Sept. 2, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Rodman & Renshaw 11th Annual Healthcare Conference at 4:05 PM EDT on Wednesday, September 9, 2009 at the New York Palace Hotel.

Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will provide a brief overview of the company's product pipeline, clinical development status and upcoming milestones.

Dr. Pedder's presentation will be webcast live and archived for 90 days on Chelsea's website, www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension, an indication for which it was approved in Japan in 1989. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051.

This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks relating to the use of the proceeds from our registered direct offering, our need to raise additional operating capital in the future, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates droxidopa and CH-1504, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for our products if any are approved for marketing, reliance on key personnel including specifically Dr. Pedder and other risks set forth in our public filings made with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K.

CONTACT:  Chelsea Therapeutics
          Nick Riehle, Chief Financial Officer
            704-341-1516 x101
          Investor/Media Relations
          Kathryn McNeil
            718-788-2856